(Q34500712)

2 August 2017

1 reference

title

Primary drug treatment for glaucoma: beta-blockers versus other medications (English)

1 reference

2 August 2017

Robert L Stamper

1

1 reference

2 August 2017

Stephen A Wigginton

series ordinal

2

1 reference

2 August 2017

Eve J Higginbotham

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2002

1 reference

2 August 2017

published in

Survey of Ophthalmology

1 reference

2 August 2017

volume

47

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

63-73

1 reference

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Effects of timolol maleate on tear flow in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Nephrolithiasis with dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Apparent central nervous system depression in infants after the use of topical brimonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Topical timolol decreases plasma high-density lipoprotein cholesterol level.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Falls in elderly patients with glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Beta-blocker eyedrops and nocturnal arterial hypotension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Reduction of IOP with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Irreversible corneal decompensation in patients treated with topical dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Topical timolol and the nursing mother

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Clinical experience with latanoprost: a retrospective study of 153 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Timolol transitory manifestations of dry eyes in long term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Timolol-induced bronchospasm in asthmatic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Corneal toxicity associated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Latanoprost and herpes simplex keratitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

Timolol maleate: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900286-7

7 January 2021

10.1016/S0039-6257(01)00286-7

Identifiers

DOI

1 reference

2 August 2017

1 reference